Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin DeficiencyPRNewsWire • 03/03/22
Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate HighlightsPRNewsWire • 02/28/22
Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent DataPRNewsWire • 01/04/22
Here's What Could Help Inhibrx, Inc. (INBX) Maintain Its Recent Price StrengthZacks Investment Research • 12/20/21
Wall Street Analysts Predict a 32% Upside in Inhibrx, Inc. (INBX): Here's What You Should KnowZacks Investment Research • 11/23/21
Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate HighlightsPRNewsWire • 11/09/21
Inhibrx, Inc. (INBX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/05/21
Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of DirectorsPRNewsWire • 10/28/21
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly DosingPRNewsWire • 10/12/21
Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin DeficiencyPRNewsWire • 10/11/21
Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with OxfordPRNewsWire • 06/21/21
Week 24 MDA Breakout Stocks - June 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 06/13/21